Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant GliomasAlessandro Canella, Vinay K. Puduvalli, Metin N. Gürcan et al.|Clinical Cancer Research|2017Cited by 69
Figure S3 from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant GliomasAlessandro Canella, Vinay K. Puduvalli, Alessandra M. Welker et al.|Unknown|2023Cited by 0
Supplemental Methods and Figure Legends from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant GliomasAlessandro Canella, Vinay K. Puduvalli, Alessandra M. Welker et al.|Unknown|2023Cited by 0
Data from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant GliomasAlessandro Canella, Vinay K. Puduvalli, Alessandra M. Welker et al.|Unknown|2023Cited by 0
Data from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant GliomasAlessandro Canella, Vinay K. Puduvalli, Alessandra M. Welker et al.|Unknown|2023Cited by 0